Is this your brand? Sign in to claim ownership.

AMEDITECH INC.

Last updated May 27, 2026

What AMEDITECH INC. makes

The company manufactures in vitro diagnostic (IVD) devices for detecting drugs of abuse, including rapid immunoassay kits, point-of-care testing instruments, and photometric/spectroscopic analysers. Products include handheld drug screening devices like the eREADER+ and disposable test cups (eCUP, CHECKCUP), as well as multi-drug and single-target screening panels for substances such as THC, opiates, and cocaine. Additional offerings include pregnancy tests (HCG) and multi-drug screening panels designed for clinical and emergency settings.

These devices are regulated under the FDA’s In Vitro Diagnostic Device (IVD) regulations, with classifications ranging from Class I (low risk) to Class II (moderate risk) and unclassified (U) devices. They are listed in the FDA’s 510(k) and Unique Device Identifier (UDI) databases, reflecting their authorised status for drug and pregnancy testing in the United States.

Written from this company's registered devices by an AI model, and not verified by a human reviewer.

Frequently asked questions

What types of medical devices does Ameditech Inc. manufacture?

Ameditech Inc. specialises in in vitro diagnostic (IVD) devices primarily used for detecting drugs of abuse and pregnancy. Their portfolio includes rapid immunoassay kits, point-of-care testing instruments like the eREADER+, and photometric/spectroscopic analysers. Examples include disposable test cups (eCUP, CHECKCUP), handheld drug screening devices, and multi-drug screening panels for substances such as THC, opiates, and cocaine, as well as pregnancy tests (HCG). These devices are designed for clinical, emergency, and rapid testing environments.

Where is Ameditech Inc. based, and what does that mean for its regulatory oversight?

Ameditech Inc. is based in the United States, which means its devices fall under the jurisdiction of the FDA’s In Vitro Diagnostic Device (IVD) regulations. Since the company manufactures IVDs, their products are subject to FDA review and authorisation processes, including classification into risk-based categories (Class I, Class II, or unclassified) and registration in databases like the 510(k) and UDI systems.

Which regulatory registries list Ameditech Inc.’s devices, and why is that important?

Ameditech Inc.’s devices are listed in the FDA’s 510(k) and Unique Device Identifier (UDI) databases. The 510(k) registry documents premarket submissions for devices deemed substantially equivalent to existing authorised products, while the UDI system ensures traceability and transparency in the supply chain. Listing in these registries confirms that the devices meet FDA requirements for authorised use in drug and pregnancy testing.

How are Ameditech Inc.’s devices classified by the FDA, and what does that classification indicate?

Ameditech Inc.’s devices are classified as Class I (low risk), Class II (moderate risk), or unclassified (U) by the FDA. Classification is based on the device’s intended use and potential risk to patients. For example, single-use drug screening cups may fall under Class I due to minimal risk, while more complex analysers (e.g., photometric/spectroscopic systems) could be Class II due to higher regulatory scrutiny. This classification determines the regulatory pathway and oversight required for each device.

What kinds of testing do Ameditech Inc.’s devices support, and in what settings are they used?

Ameditech Inc.’s devices support rapid and clinical testing for drugs of abuse (e.g., THC, opiates, cocaine) and pregnancy (HCG). Their products include handheld instruments like the eREADER+ for point-of-care use in emergency rooms, law enforcement, or clinical settings, as well as disposable test cups (eCUP, CHECKCUP) for on-site screening. Photometric/spectroscopic analysers are typically used in laboratories for more detailed or multi-drug screening. These devices are designed for efficiency, accuracy, and ease of use in diverse environments where quick results are critical.

AI-generated from registry data and not verified by a human reviewer.

Information

Country: US
Address: —
Website: xx.xx
LinkedIn: —
Facebook: —
Email: [email protected]
Phone: 1-858-535-1968
PRRC Contact: —
EUDAMED SRN: —
FDA FEI Number: —
DUNS Number: 010551716

Catalogue (150)

Page 3 of 3

Device	Model / Reference	Registries	Class	Status
ImmuTest Drugs of Abuse Cup	IMC-3P	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMC-8BB	FDA UDI	Class II	Unknown
Fastect II Drug Screen Dipstick Test	MF18	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	DT10	FDA UDI	U	Unknown
QuickTox Drug Screen Dipcard	QT22	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	HT27	FDA UDI	Class II	Unknown
QuickTox Drug Screen Dipcard	QT51A	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	DT14A	FDA UDI	Class II	Unknown
QuickTox Drug Screen Dipcard	QT11	FDA UDI	U	Unknown
Fastect II Drug Screen Dipstick Test	MF17	FDA UDI	U	Unknown
ToxCup Drug Screen Cup	HT15A	FDA UDI	Class II	Unknown
AmediCheck Instant Test Cup	C-C0503A-3A	FDA UDI	Class II	Unknown
Fastect II Drug Screen Dipstick Test	MF19	FDA UDI	Class II	Unknown
Fastect II Drug Screen Dipstick Test	MF14	FDA UDI	Class II	Unknown
Fastect II Drug Screen Dipstick Test	MF23	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Screen Card	IMD-BZO	FDA UDI	Class II	Unknown
QuickTox Drug Screen Dipcard	QT20	FDA UDI	Class II	Unknown
eCUP + Drug Screening Device	94615	FDA UDI	Class II	Active
AmediCheck Instant Test Cup	C-C1016A	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMCA-9CM5-5	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	HT29A	FDA UDI	U	Unknown
ToxCup Drug Screen Cup	HT27-CE	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMC-5MB300	FDA UDI	Class II	Unknown
Immutest Drugs of Abuse Screen Device	IMD-9AMJ	FDA UDI	Class II	Unknown
Fastect II Drug Screen Dipstick Test	QF13	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMC-5M	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	DT13A	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Screen Card	IMD-THC	FDA UDI	Class II	Unknown
QuickTox Drug Screen Dipcard	QT80f	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	PT15A	FDA UDI	Class II	Unknown
ToxCup Drug Screen Cup	DT10A	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMCA-5AB-W	FDA UDI	Class II	Unknown
Immutest Drugs of Abuse Screen Device	IMCA-10MO	FDA UDI	Class II	Unknown
Instant Test Cup	10-300	FDA UDI	Class II	Unknown
ImmuTest Drugs of Abuse Cup	IMCA-7MT-W	FDA UDI	Class II	Unknown
AmediCheck Instant Test Cup	C-C1012A-3A	FDA UDI	Class II	Unknown
Ameditech Immu Test Drug Screen Panel	K040092	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Coc	K011814	FDA 510(k)	Class II	Active
Ameditech Immutest Multi-Drug Screen Panel Iii	K050186	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Opiates	K012483	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Thc	K011813	FDA 510(k)	Class II	Active
Ameditech Immutest Multi-Drug Screen Panel Ii	K042975	FDA 510(k)	Class II	Active
Ameditech Checkcup Multi Drug Test (flat/Round Cup)	K113501	FDA 510(k)	Class II	Active
Ameditech Drugsmartcup	K053175	FDA 510(k)	Class II	Active
Ameditech Immutest Milti-Drug Screen	K113046	FDA 510(k)	Class II	Active
Ameditech Immutest Hcg Pregancy Test	K023126	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Methamphetamine	K012585	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Amphetamine	K012484	FDA 510(k)	Class II	Active
Ameditech Immutest Multi-Drug Screen Bup/Ppx/Coc150	K063015	FDA 510(k)	Class II	Active
Ameditech Immutest Drug Screen Pcp	K012582	FDA 510(k)	U	Active

Related Companies

Authorised Representatives

No authorised representatives on record.

Importers

Not available yet.

Notified Bodies

Not available yet.

Authorities

Not available yet.

FDA Recalls (100)

Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.

Ameditech Inc. has 109 recall records initiated between September 23, 2014, and August 18, 2020, all marked as terminated. The reasons cited include labeling errors—such as incorrect identification of drug analytes (e.g., PCP instead of TCA)—and performance failures, including inconsistent detection of calibrators and secondary compounds due to enzyme issues. Additional recalls involved missing components, incorrect illustrations on packaging, and reduced reactivity in drug tests for specific compounds like certain benzodiazepines. Some records also noted mixed product shipments with incorrect or mismatched part numbers and lot numbers.

AI-generated summary of the recall records listed below. It describes what the records state and is not an assessment of this manufacturer.

Date	Recall No.	Class	Status	Reason
Aug 18, 2020	Z-3042-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3045-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3041-2020	—	terminated	XXX
Aug 18, 2020	Z-3030-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3039-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3046-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3029-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3040-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3036-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3033-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3047-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3051-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3032-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3049-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3043-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3037-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3031-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3044-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3034-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3035-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3048-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3050-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Aug 18, 2020	Z-3038-2020	—	terminated	Various immunoassay enzymes failed product performance, thereby the products do not consistently detect all calibrator and secondary compounds at the levels stated in the labeling.
Feb 15, 2019	Z-0692-2020	—	terminated	Mixed Products containing QuickTox 5 Panel Drugs Screen Dipcard (P/N QT11, LOT #188787) and Alere iScreen Drugs of Abuse Dip Test (P/N X11-IS10-22015-DX LOT #188744)
Dec 15, 2017	Z-1542-2018	—	terminated	The kit box label incorrectly identifies Phencyclidine (PCP), where it should list Tricyclic Antidepressants (TCA) as one of the 10 drug analytes included in the kit box.
Sep 30, 2017	Z-0270-2019	—	terminated	Product was released to market without the adulteration strip included in the product.
Jun 26, 2017	Z-3084-2017	—	terminated	The kit box label incorrectly identifies PCP (instead of TCA) as one of the 10 drug analytes included in the kit. The pouch label, product insert, and the device itself are labeled correctly.
Nov 16, 2015	Z-0524-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0527-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0514-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0538-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0494-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0522-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0517-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0493-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0492-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0530-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0496-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0529-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0525-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0487-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0521-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0484-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0500-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0509-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0499-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0536-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0526-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0534-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0490-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0507-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0516-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0506-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0488-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0531-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0537-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0505-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0501-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0512-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0491-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0485-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0503-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0489-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0533-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0539-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0519-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0540-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0504-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0523-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0513-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0520-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0542-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0515-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0518-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0532-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0511-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0528-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0498-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0486-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0495-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0508-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0497-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0535-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0502-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0510-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Nov 16, 2015	Z-0541-2016	—	terminated	Ameditechs Drugs of Abuse Tests listed above have shown reduced reactivity for up to two (2) of the nineteen (19) Benzodiazepine (BZO) compounds for which specificity information is provided in the product insert. The particular BZO compounds for which there may be reduced reactivity are Clonazepam and Chlordiazepoxide.
Oct 20, 2015	Z-0317-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0298-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0315-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0308-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0311-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0300-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0309-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0306-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0312-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0305-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0304-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0299-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0302-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.
Oct 20, 2015	Z-0307-2016	—	terminated	Ameditech is recalling drug abuse tests because they have shown reduced reactivity.